ArticleToxicology and applied pharmacology2025
Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice.
Article in Toxicology and applied pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a spectrum of chronic pathologic conditions strongly associated with metabolic syndrome and affects approximately 38 % of the global population. Untreated MASLD may progress to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and cirrhosis and is currently recognized as one of the main risk factors for hepatocellular carcinoma (HCC). The molecular determinants of MASLD stratification are not clearly defined and require additional investigation. In this study, we used a dietary preclinical model of MASH-like liver injury induced by feeding male and female Collaborative Cross CC042/GeniUnc mice a high-fat and high-sucrose diet (HF/HS) for up to 60 weeks and analyzed the global hepatic transcriptomic alterations. Chronic feeding the HF/HS diet induced profound alterations in liver gene expression associated with the key toxicity pathways, including cell death, cell proliferation, inflammation, fibrosis, and hyperplasia. We identified a panel of 74 differentially expressed genes, the expression of which significantly correlated with total MASH pathology scores in the livers of both male and female mice. Using these genes, we developed a machine-learning model that accurately predicted the severity of MASH-like liver injury in several different animal models of MASH and demonstrated high accuracy for a smaller model with 37 genes. We also used this signature to analyze human gene expression data and show its translational relevance. The results of this study demonstrate that a panel of MASH-related genes can assist in the assessment of MASH-like liver injury, its monitoring, and in development of mechanism-based drugs against MASH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.